"Baber Research Group is a distinguished leader in Clinical Research - advancing medicine and science. Our passion is improving the quality of life, finding cures, and preventing diseases."

During the past decade, AMR-Baber Research Inc. conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 17 clinical trials were completed, i.e. on average, 94.4% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 7 clinical trials were completed. i.e. 87.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "AMR-Baber Research Inc." #1 sponsor was "Shire" with 7 trials, followed by "Pfizer" with 5 trials sponsored, "Naurex, Inc, an affiliate of Allergan plc" with 4 trials sponsored, "Biohaven Pharmaceuticals, Inc." with 3 trials sponsored and "Sunovion" with 3 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "AMR-Baber Research Inc." #1 collaborator was "Autism Speaks" with 2 trials as a collaborator, "GlaxoSmithKline" with 1 trials as a collaborator and "Takeda" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "AMR-Baber Research Inc." are "Depressive Disorder, Major" (5 trials), "Major Depressive Disorder" (4 trials), "Attention Deficit Hyperactivity Disorder" (3 trials), "Attention Deficit Hyperactivity Disorder (ADHD)" (2 trials) and "Attention-Deficit/Hyperactivity Disorder" (2 trials). Many other conditions were trialed in "AMR-Baber Research Inc." in a lesser frequency.

Most popular intervention types in "AMR-Baber Research Inc." are "Drug" (33 trials), "Other" (6 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (20 trials), "Rapastinel" (4 trials), "Ecopipam" (2 trials), "Extended-release Guanfacine Hydrochloride" (2 trials) and "Fluoxetine" (2 trials). Other intervention names were less common.

The vast majority of trials in "AMR-Baber Research Inc." are 34 trials for "All" genders.

Currently, there are NaN active trials in "AMR-Baber Research Inc.". undefined are not yet recruiting, 4 are recruiting, 1 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 25 completed trials in AMR-Baber Research Inc., undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in AMR-Baber Research Inc., 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 24 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 1 trials that are defined as “Not Applicable".